Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

101.72USD
18 Jan 2018
Change (% chg)

-- (--)
Prev Close
$101.72
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,440,883
52-wk High
$147.13
52-wk Low
$94.56

Latest Key Developments (Source: Significant Developments)

Celgene Is In Talks To Buy Juno Therapeutics -WSJ Reporter Tweet‍​
Wednesday, 17 Jan 2018 

Jan 16 (Reuters) - :CELGENE IS IN TALKS TO BUY JUNO THERAPEUTICS -WSJ REPORTER TWEET‍​.  Full Article

Celgene CEO Says Plans To Invest Heavily In R&D In 2018
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Celgene Corp ::CELGENE CEO SAYS PLANS TO INVEST HEAVILY IN RESEARCH AND DEVELOPMENT, BUSINESS DEVELOPMENT IN 2018.CELGENE SAYS HAS 10 LATE STAGE MOLECULES WITH BILLION TO MULTIBILLION-DOLLAR POTENTIAL; COULD ADD MORE THAN $15 BILLION PEAK REVENUE.  Full Article

Celgene Says Expects FY 2018 Rev To Be About $14.4 Bln To $14.8 Bln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Celgene Corp ::SEES PRELIMINARY Q4 REVLIMID SALES $2,188 MILLION.ORATION ANNOUNCES PRELIMINARY 2017 UNAUDITED RESULTS AND 2018 FINANCIAL GUIDANCE.SEES Q4 2017 ADJUSTED EARNINGS PER SHARE ABOUT $2.00.SEES FY 2017 GAAP EARNINGS PER SHARE $3.64 TO $4.19.SEES Q4 2017 GAAP LOSS PER SHARE $0.09 TO $+0.46.SEES FY 2018 REVENUE UP 12 PERCENT.SEES FY 2018 REVENUE ABOUT $14.4 BILLION TO $14.8 BILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $8.70 TO $8.90.SEES FY 2020 REVENUE $19 BILLION TO $20 BILLION.SEES FY 2017 ADJUSTED EARNINGS PER SHARE ABOUT $7.44.Q4 REVENUE $3.5 BILLION VERSUS I/B/E/S VIEW $3.46 BILLION.SEES PRELIMINARY Q4 OTEZLA SALES $371 MILLION.FY2017 EARNINGS PER SHARE VIEW $7.34, REVENUE VIEW $12.98 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $8.71, REVENUE VIEW $14.83 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $1.93, REVENUE VIEW $3.46 BILLION -- THOMSON REUTERS I/B/E/S.REAFFIRMING 2020 TOTAL REVENUE AND ADJUSTED DILUTED EPS FINANCIAL TARGETS.FULL YEAR 2017 GAAP OPERATING MARGIN IS EXPECTED TO BE ABOUT 36 PERCENT.CELGENE - ESTIMATED GAAP EARNINGS PER SHARE FOR QUARTER & YEAR ENDED DEC 31, 2017 INCLUDE ESTIMATED IMPACT OF ABOUT $800 MILLION-ABOUT $1,300 MILLION DUE TO TAX CUTS AND JOBS ACT.‍BASED ON GAAP, EPS FOR FULL-YEAR 2018 IS EXPECTED TO BE IN RANGE OF $6.58 TO $6.95​.  Full Article

Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Celgene Corp :Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma.Celgene Corp - ‍designations based on preliminary clinical data from ongoing phase i study of bb2121 in heavily pre-treated multiple myeloma​.Celgene Corp - ‍updated data from CRB-401 is scheduled to be presented at 59(th) annual meeting of american society of hematology in Atlanta​.  Full Article

Celgene prices $3 billion of senior unsecured notes
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Celgene Corp :Celgene prices $3 billion of senior unsecured notes.Celgene Corp - ‍announced pricing of three series of senior unsecured notes for aggregate principal amount of $3,000 million​.  Full Article

Celgene announces offering of senior unsecured notes
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Celgene Corp :Celgene announces offering of senior unsecured notes.Celgene-To use proceeds for repayment of $1 billion outstanding 2.125% senior notes & $400 million outstanding 2.300% senior notes, each maturing Aug 2018​.  Full Article

Lannett and Celgene enter into settlement and license agreement related to Thalomid
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Celgene Corp :Lannett and Celgene enter into settlement and license agreement related to Thalomid.Lannett - ‍subject to FDA approval of co's ANDA for thalidomide, co intends to launch product under terms of license agreement, which are confidential​.Lannett-‍license agreement permits co to manufacture, market in U.S. generic thalidomide product as of Aug 1, 2019 or earlier under certain circumstances​.  Full Article

Celgene Corp updates on court order at request of Canadian Competition Bureau - SEC filing
Friday, 27 Oct 2017 

Oct 26 (Reuters) - Celgene Corp :Celgene Corp says ‍​in Aug, co received an order issued by the Federal Court in Ottawa, Ontario, Canada at request of Canadian Competition Bureau.Celgene Corp - Order requires that co provide certain materials and information relating to co's risk management program.Celgene Corp - Order also requires that co provide requests by generic manufacturers to purchase Celgene's products in Canada.Celgene Corp says it is cooperating with the request of the Canadian Competition Bureau.  Full Article

Celgene initiating share repurchase plan
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Celgene Corp :Celgene CFO says initiating share repurchase plan beginning immediately.  Full Article

Celgene reports Q3 earnings per share of $1.21
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Celgene Corp :Celgene reports third quarter 2017 operating and financial results.Q3 revenue $3.287 billion versus I/B/E/S view $3.42 billion.Q3 earnings per share $1.21.Q3 earnings per share view $1.87 -- Thomson Reuters I/B/E/S.Celgene Corp - ‍updating 2017 guidance and financial targets for 2020​.Celgene Corp - qtrly ‍revlimid sales for Q3 increased 10 percent to $2,081 million​.Celgene Corp - sees ‍2017 GAAP diluted EPS $4.78 to $5.19​.Celgene Corp - qtrly ‍ Abraxane sales for Q3 were $251 million, an 8 percent increase year-over-year​.Celgene Corp - sees 2017‍ adjusted diluted EPS $7.30 to $7.35​.Celgene Corp sees ‍2017 total revenue approximately $13.0 billion​.Celgene Corp - qtrly ‍ Otezla sales for Q3 were $308 million, a 12 percent increase year-over-year​.Celgene Corp - sees ‍ 2017 GAAP operating margin approximately 37.5%​.Fy2017 earnings per share view $7.31, revenue view $13.23 billion -- Thomson Reuters I/B/E/S.Celgene Corp sees ‍2017 Otezla sales approximately $1.25 billion​.Celgene Corp qtrly adjusted EPS ‍$1.91​.  Full Article

Celgene in talks to buy Juno Therapeutics: WSJ

Shares of Juno, which has a market value of $5.57 billion, were up 42 percent at $64.59 in extended trading.